MADRIGAL PHARMACEUTICALS, INC.
MDGL evidence brief
What we can confirm
- BioSniper Score:
- 5.0 / 10
- Market Cap:
- $12.34B
- Lead Asset:
- ervogastat (Phase 2)
What it means
What to watch
Prepared research question
What matters most for MDGL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MDGL
MADRIGAL PHARMACEUTICALS is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for metabolic dysfunction-associated steatohepatitis (MASH), anchored by its approved drug Rezdiffra.
Key risk: Single-product dependence
BioSniper Score
Based on 4 of 6 signals
Market Cap
$12.34B
Cash Runway
—
Lead Asset
ervogastat (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 12 clinical trials for MADRIGAL PHARMACEUTICALS, INC..
Similar companies
MADRIGAL PHARMACEUTICALS is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for metabolic dysfunction-associated steatohepatitis (MASH), anchored by its approved drug Rezdiffra.
- Rezdiffra generated $958.4 million in net sales in its first full year on the market (2025) and exited the year with quarterly revenue annualizing at over $1 billion [sec · filed 2026-04-28].
- As of 2026-06-30, the company reported cash & equivalents of $292.7M, total revenue of $364.3M, and a net loss of -$57.9M [sec].
- The pipeline has expanded to more than ten programs, including an oral GLP-1 (MGL-2086), a DGAT-2 inhibitor (ervogastat), and six siRNA programs [sec · filed 2026-04-28].
- Rezdiffra is being evaluated in compensated MASH cirrhosis (F4c) in the MAESTRO-NASH OUTCOMES trial, which could expand the eligible patient population [sec_mda · as of 2026-07-30].
- The company launched Rezdiffra in Germany in 2025 following Conditional Marketing Authorization from the European Commission [sec · filed 2026-04-28].
What works
- Rezdiffra has achieved a strong commercial launch, with net sales of $958.4 million in 2025 and quarterly revenue annualizing over $1 billion, establishing it as the foundational therapy in MASH [sec · filed 2026-04-28].
- The company has built a broad pipeline of more than ten programs, including complementary mechanisms such as an oral GLP-1, a DGAT-2 inhibitor, and six siRNA programs, positioning it for long-term leadership in MASH [sec · filed 2026-04-28].
- Madrigal secured broad first-line access with major commercial payors for 2026 and maintained a favorable gross-to-net discount in 2025, supporting patient access to Rezdiffra [sec · filed 2026-04-28].
What to weigh
- The company reported a net loss of -$57.9M for the period ending 2026-06-30, and management expects to continue incurring losses until Rezdiffra and other products generate sufficient revenue [sec_mda · as of 2026-07-30].
- Madrigal has total debt of $471.9M as of 2026-06-30, and its cash usage is expected to increase to support pipeline development, commercialization, and geographic expansion [sec_mda · as of 2026-07-30].
- The company's financial performance remains dependent on the commercial success of a single approved product (Rezdiffra), and pipeline programs are still in early to mid-stage development with no near-term revenue contribution [sec · filed 2026-04-28].
From the filings
Quoted directly from source documents.
Rezdiffra's first full-year net sales were $958.4 million.
“We ended our first full year on the market with $958.4 million in net sales”
SEC filings · April 28, 2026
The pipeline includes more than ten programs, including an oral GLP-1, a DGAT-2 inhibitor, and six siRNA programs.
“we have expanded our pipeline to more than ten programs, including an oral GLP-1, a late-stage DGAT-2 inhibitor (ervogastat) and a portfolio of six siRNA programs”
SEC filings · April 28, 2026
Rezdiffra is being evaluated in compensated MASH cirrhosis (F4c) in the MAESTRO-NASH OUTCOMES trial.
“We are also evaluating Rezdiffra in patients with compensated MASH cirrhosis (consistent with F4c fibrosis) in our MAESTRO-NASH OUTCOMES trial”
SEC MD&A · July 30, 2026
Risks & what to watch (4)›
Key risks
- Single-product dependence — Revenue relies almost entirely on Rezdiffra; pipeline programs are early-stage and not yet revenue-generating [sec · filed 2026-04-28].
- Ongoing net losses — Net loss of -$57.9M as of 2026-06-30; losses expected to continue until revenue from Rezdiffra and other products grows [sec_mda · as of 2026-07-30].
- High debt and cash burn — Total debt of $471.9M and cash usage expected to increase for pipeline and geographic expansion [sec_mda · as of 2026-07-30].
- Clinical trial risk for F4c — Success of MAESTRO-NASH OUTCOMES trial is uncertain; failure would limit patient population expansion [sec_mda · as of 2026-07-30].
What to watch
- Progress of the MAESTRO-NASH OUTCOMES trial evaluating Rezdiffra in compensated MASH cirrhosis (F4c) [sec_mda · as of 2026-07-30].
- Commercial execution of Rezdiffra in Europe, particularly following the German launch and country-by-country expansion [sec · filed 2026-04-28].
- Pipeline advancement of oral GLP-1 (MGL-2086), DGAT-2 inhibitor (ervogastat), and siRNA programs into later-stage trials [sec · filed 2026-04-28].
- Financial trajectory, including ability to reduce net losses and manage debt of $471.9M as of 2026-06-30 [sec].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 11, 2026 · How we verify sources →
Run MADRIGAL PHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MADRIGAL PHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.38 · 0% dilution
Lead: Phase 2
3 candidates
No upcoming catalysts tracked
0 buys · 25 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 19.7%
- Days to cover
- 13.3
- Shares short
- 3,854,441
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MDGL short interestGovernance
Frequently asked questions
What is the AI investment thesis for MADRIGAL PHARMACEUTICALS, INC.?
MADRIGAL PHARMACEUTICALS is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for metabolic dysfunction-associated steatohepatitis (MASH), anchored by its approved drug Rezdiffra.
What is MADRIGAL PHARMACEUTICALS, INC.'s lead drug candidate?
MADRIGAL PHARMACEUTICALS, INC.'s most advanced tracked candidate is ervogastat (Phase 2) for Metabolic dysfunction-associated steatohepatitis (MASH).
Who is the CEO of MADRIGAL PHARMACEUTICALS, INC.?
Mr. William J. Sibold is the chief executive officer of MADRIGAL PHARMACEUTICALS, INC. (MDGL).
Where is MADRIGAL PHARMACEUTICALS, INC. headquartered?
MADRIGAL PHARMACEUTICALS, INC. (MDGL) is headquartered in West Conshohocken, PA, United States.
What therapeutic areas does MADRIGAL PHARMACEUTICALS, INC. focus on?
MADRIGAL PHARMACEUTICALS, INC. develops therapies across Cardiovascular, Infectious Disease, Metabolic, Nephrology, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.